Early administration of nirmatrelvir/ritonavir leads to faster negative SARS-CoV-2 nasal swabs than monoclonal antibodies in COVID 19 patients at high-risk for severe disease
Purpose Besides the well-established efficacy in preventing severe COVID-19, the impact of early treatments, namely antivirals and monoclonal antibodies (mAbs), on the time length to negativization of SARS-CoV-2 nasal swabs is still unclear. The aim of this study was to compare the efficacy of different early treatments in reducing the SARS-CoV-2 viral shedding, identifying a single drug that might potentially lead to a more rapid negativization of SARS-CoV-2 nasal swab. Methods This was a single-centre, retrospective, observational study conducted at Ospedale Luigi Sacco in Milan. Data of high-risk COVID-19 patients who received early treatments between 23 December 2021 and March 2023 were extracted. The comparison across treatments was conducted using the Kruskall-Wallis test for continuous variables. Dunn’s test with Bonferroni adjustment was performed for post-hoc comparisons of days to negativization. Secondly, a negative binomial regression adjusted for age, sex, number of comorbidities, immunosuppression, and SARS-CoV-2 vaccination status was implemented. Results Data from 428 patients receiving early treatments were collected. The majority were treated with Nirmatrelvir/Ritonavir and were affected by SARS-CoV-2 Omicron infection with BA.2 sublineage. The median length time to SARS-CoV-2 nasal swab negativization was 9 days [IQR 7–13 days]. We found that Nirmatrelvir/Ritonavir determined a significant decrease of the length time to SARS-CoV-2 nasal swab negativization compared to mAbs (p = 0.003), but not compared to Remdesivir (p = 0.147) and Molnupiravir (p = 0.156). Conclusion Our findings highlight the importance of promptly treating high-risk COVID-19 patients with Nirmatrelvir/Ritonavir, as it also contributes to achieving a faster time to negative SARS-CoV-2 nasal swabs..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:21 |
|---|---|
| Enthalten in: |
Virology journal - 21(2024), 1 vom: 20. März |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Colaneri, Marta [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
COVID-19 |
|---|
| Anmerkungen: |
© The Author(s) 2024 |
|---|
| doi: |
10.1186/s12985-024-02333-x |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR055229980 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR055229980 | ||
| 003 | DE-627 | ||
| 005 | 20240321064716.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240321s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s12985-024-02333-x |2 doi | |
| 035 | |a (DE-627)SPR055229980 | ||
| 035 | |a (SPR)s12985-024-02333-x-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q VZ |
| 100 | 1 | |a Colaneri, Marta |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Early administration of nirmatrelvir/ritonavir leads to faster negative SARS-CoV-2 nasal swabs than monoclonal antibodies in COVID 19 patients at high-risk for severe disease |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s) 2024 | ||
| 520 | |a Purpose Besides the well-established efficacy in preventing severe COVID-19, the impact of early treatments, namely antivirals and monoclonal antibodies (mAbs), on the time length to negativization of SARS-CoV-2 nasal swabs is still unclear. The aim of this study was to compare the efficacy of different early treatments in reducing the SARS-CoV-2 viral shedding, identifying a single drug that might potentially lead to a more rapid negativization of SARS-CoV-2 nasal swab. Methods This was a single-centre, retrospective, observational study conducted at Ospedale Luigi Sacco in Milan. Data of high-risk COVID-19 patients who received early treatments between 23 December 2021 and March 2023 were extracted. The comparison across treatments was conducted using the Kruskall-Wallis test for continuous variables. Dunn’s test with Bonferroni adjustment was performed for post-hoc comparisons of days to negativization. Secondly, a negative binomial regression adjusted for age, sex, number of comorbidities, immunosuppression, and SARS-CoV-2 vaccination status was implemented. Results Data from 428 patients receiving early treatments were collected. The majority were treated with Nirmatrelvir/Ritonavir and were affected by SARS-CoV-2 Omicron infection with BA.2 sublineage. The median length time to SARS-CoV-2 nasal swab negativization was 9 days [IQR 7–13 days]. We found that Nirmatrelvir/Ritonavir determined a significant decrease of the length time to SARS-CoV-2 nasal swab negativization compared to mAbs (p = 0.003), but not compared to Remdesivir (p = 0.147) and Molnupiravir (p = 0.156). Conclusion Our findings highlight the importance of promptly treating high-risk COVID-19 patients with Nirmatrelvir/Ritonavir, as it also contributes to achieving a faster time to negative SARS-CoV-2 nasal swabs. | ||
| 650 | 4 | |a COVID-19 |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Monoclonal antibodies |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Time to negativization |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Immunosuppression |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Nirmatrelvir/Ritonavir |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Scaglione, Giovanni |4 aut | |
| 700 | 1 | |a Fassio, Federico |4 aut | |
| 700 | 1 | |a Galli, Lucia |4 aut | |
| 700 | 1 | |a Lai, Alessia |4 aut | |
| 700 | 1 | |a Bergna, Annalisa |4 aut | |
| 700 | 1 | |a Gabrieli, Arianna |4 aut | |
| 700 | 1 | |a Tarkowski, Maciej |4 aut | |
| 700 | 1 | |a Ventura, Carla Della |4 aut | |
| 700 | 1 | |a Colombo, Valeria |4 aut | |
| 700 | 1 | |a Cordier, Laura |4 aut | |
| 700 | 1 | |a Bernasconi, Davide |4 aut | |
| 700 | 1 | |a Corbellino, Mario |4 aut | |
| 700 | 1 | |a Dedivitiis, Gianfranco |4 aut | |
| 700 | 1 | |a Borghetti, Silvia |4 aut | |
| 700 | 1 | |a Visigalli, Debora |4 aut | |
| 700 | 1 | |a Sollima, Salvatore |4 aut | |
| 700 | 1 | |a Casalini, Giacomo |4 aut | |
| 700 | 1 | |a Rizzardini, Giuliano |4 aut | |
| 700 | 1 | |a Gori, Andrea |4 aut | |
| 700 | 1 | |a Antinori, Spinello |4 aut | |
| 700 | 1 | |a Riva, Agostino |4 aut | |
| 700 | 1 | |a Schiavini, Monica |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Virology journal |d BioMed Central, 2004 |g 21(2024), 1 vom: 20. März |w (DE-627)SPR029231027 |w (DE-600)2160640-7 |x 1743-422X |7 nnns |
| 773 | 1 | 8 | |g volume:21 |g year:2024 |g number:1 |g day:20 |g month:03 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1186/s12985-024-02333-x |z kostenfrei |3 Volltext |
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |d 21 |j 2024 |e 1 |b 20 |c 03 | ||